Vaccine makers in the U.S. are feeling a real chill in demand and investor confidence as sweeping policy changes under Health Secretary Robert F. Kennedy Jr. shift longstanding vaccination recommendations and dilute broad vaccine guidance. Long-standing inoculation schedules (like flu and hepatitis shots for kids) have been cut back, expert advisory panels replaced, and COVID vaccine recommendations for pregnant women and children dropped, moves that are now translating into lower usage and weaker sales forecasts. Investors say this uncertainty has dented the growth case for some biotech names and could weigh on revenues for years. Big pharma names like $PFE, $MRK, $GSK, and smaller players like $MRNA, $NVAX, $BNTX are now having to wrestle with a more unpredictable U.S. vaccine market while broader public health experts warn of rising preventable disease risk. This isn’t just political noise anymore, policy shifts are hitting the core of vaccine demand, making it harder for some companies to forecast growth and justify investment. How much do you think U.S. policy shifts will dent long-term vaccine demand and biotech investor confidence?